The objectives of this study were to evaluate current patterns of use, microbiologic cure rates, and hematologic toxicities, including identification of risk factors, associated with linezolid utilization at our institution.
Methods
Utilization, clinical, microbiological, and toxicity data were collected prospectively over an 8-month period (August 1, 2006 to March 31, 2007). Binary logistic and multivariate stepwise regression analyses were performed to identify potential risk factors for linezolid-associated thrombocytopenia and anemia.
Results
A total of 116 linezolid courses (102 patients) were identified with a mean duration of therapy of 12.3 days. Appropriate infectious disease service approval and consults were found in 87.9% and 62.1% of the cases, respectively. Bloodstream, urinary tract, and respiratory tract infections accounted for 29%, 21%, and 16% of clinical indications, respectively. Vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and coagulase-negative staphylococci accounted for 43%, 24%, and 7% of clinical isolates, respectively. Overall, the microbiologic cure rate among evaluable patients was 83.8%. Development of thrombocytopenia was found in approximately 30% of linezolid-treated patients. Risk factors for linezolid-associated thrombocytopenia included female gender (OR 5.66, P = .002), serum creatinine (SCr) ≥ 2 mg/dL (OR 4.48, P = .009), intensive care unit admission (OR 3.06, P = .038), and duration of therapy ≥ 28 days (OR 3.76, P = .049).
Conclusion
Utilization patterns may suggest strategies for conserving linezolid, including improved compliance with current approval policies and clinical pathway development. Linezolid microbiological cure rates were similar to those found in the primary literature. Linezolid-associated thrombocytopenia was common and risk factors were identified. Further well-designed prospective studies are needed to confirm these findings.
DiekemaD.J., PfallerM.A., SchmitzF.J.Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis.2001; 32(Suppl 2): S114–132.
3.
DoernG.V., JonesR.N., PfallerM.A., KuglerK.C., BeachM.L.Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis.1999; 34(1): 65–72.
4.
RiceL.B.Emergence of vancomycin-resistant enterococci. Emerg Infect Dis.2001; 7(2): 183–187.
5.
RiceL.B.Antimicrobial resistance in gram-positive bacteria. Am J Med.2006; 119(6 Suppl 1): S11–19; discussion S62-70.
6.
RichardsM.J. E.J., CulverD.H., GaynesR.P.Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol.2000; 21: 510–515.
ShorrA.F.Epidemiology of staphylococcal resistance. Clin Infect Dis.2007; 45(Suppl 3): S171–176.
14.
LivermoreD.M.Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother.2003; 51(Suppl 2): ii9–16.
15.
PaladinoJ.A.Linezolid: an oxazolidinone antimicrobial agent. Am J Health Syst Pharm.2002; 59(24): 2413–2425.
16.
WilcoxM.H.Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother.2005; 6(13): 2315–2326.
17.
AksoyD.Y., UnalS.New antimicrobial agents for the treatment of gram-positive bacterial infections. Clin Microbiol Infect.2008; 14(5): 411–420.
18.
MacGowanA.P.Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother.2003; 51(Suppl 2): ii17–25.
19.
StalkerD.J., JungbluthG.L.Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharma-cokinet.2003; 42(13): 1129–1140.
20.
VardakasK.Z., NtzioraF., FalagasM.E.Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother.2007; 8(14): 2381–2400.
21.
DrewR.H.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy.2007; 27(2): 227–249.
22.
ScheetzM.H., QiC., NoskinG.A.The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn Microbiol Infect Dis.2006; 56(4): 407–413.
WilcoxM., NathwaniD., DrydenM.Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother.2004; 53(2): 335–344.
25.
GersonS.L., KaplanS.L., BrussJ.B.Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother.2002; 46(8): 2723–2726.
26.
RubinsteinE., IsturizR., StandifordH.C.Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother.2003; 47(6): 1824–1831.
BirminghamM.C., RaynerC.R., MeagherA.K., FlavinS.M., BattsD.H., SchentagJ.J.Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis.2003; 36(2): 159–168.
29.
BishopE., MelvaniS., HowdenB.P., CharlesP.G., GraysonM.L.Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother.2006; 50(4): 1599–1602.
30.
ChenY.S., LeeS.C., KimW.J.Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by Gram-positive pathogens. J Formos Med Assoc.2004; 103(5): 349–354.
31.
NasrawayS.A., ShorrA.F., KuterD.J., O'GradyN., LeV.H., CammarataS.K.Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis.2003; 37(12): 1609–1616.
32.
OrrickJ.J., JohnsT., JanelleJ., RamphalR.Thrombocytopenia secondary to linezolid administration: what is the risk?Clin Infect Dis.2002; 35(3): 348–349.
33.
SennevilleE., LegoutL., ValetteM.Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother.2004; 54(4): 798–802.
34.
SmithP.F., BirminghamM.C., NoskinG.A.Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram-positive infections in cancer patients with neutropenia. Ann Oncol.2003; 14(5): 795–801.
35.
GrauS., Morales-MolinaJ.A., Mateu-de AntonioJ., Marin-CasinoM., Alvarez-LermaF.Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother.2005; 56(2): 440–441.
36.
BabcockH.M. F.V.Clinical experience with linezolid: a case series of 53 patients. Infect Dis Clin Pract.2002; 11: 198–204.
37.
PughR.N., Murray-LyonI.M., DawsonJ.L., PietroniM.C., WilliamsR.Transection of the oesophagus for bleeding oesophageal varices. Br J Surg.1973; 60(8): 646–649.
38.
WilcoxM.H., TackK.J., BouzaE.Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis.2009; 48(2): 203–212.0
39.
FalagasM.E., SiemposI.I., VardakasK.Z.Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis.2008; 8(1): 53–66.
40.
JantauschB.A., DevilleJ., AdlerS.Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J.2003; 22(9 suppl): S164–171.
41.
JaureguiL.E., BabazadehS., SeltzerE.Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis.2005; 41(10): 1407–1415.
42.
KaplanS.L., DevilleJ.G., YogevR.Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J.2003; 22(8): 677–686.
43.
LipskyB.A., ItaniK., NordenC.Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis.2004; 38(1): 17–24.
44.
RaoN., HamiltonC.W.Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis.2007; 59(2): 173–179.
45.
RubinsteinE., CammarataS., OliphantT., WunderinkR.Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis.2001; 32(3): 402–412.
46.
San PedroGSCS, OliphantT.H., TodiscoT.Linezolid Community-Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis.2002; 34: 720–728.
47.
SharpeJ.N., ShivelyE.H., PolkHCJrClinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant. Staphylococcus aureus. Am J Surg.2005; 189(4): 425–428.
48.
ShorrA.F., KunkelM.J., KollefM.Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother.2005; 56(5): 923–929.
49.
StevensD.L., HerrD., LampirisH., HuntJ.L., BattsD.H., HafkinB.Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis.2002; 34(11): 1481–1490.
50.
WeigeltJ., ItaniK., StevensD., LauW., DrydenM., KnirschC.Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother.2005; 49(6): 2260–2266.
51.
WibleK., TregnaghiM., BrussJ., FleishakerD., Naberhuis-StehouwerS., HiltyM.Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J.2003; 22(4): 315–323.
52.
WilcoxM.H.Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother.2003; 51(Suppl 2): ii27–35.
53.
WunderinkR.G., RelloJ., CammarataS.K., Croos-DabreraR.V., KollefM.H.Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest.2003; 124(5): 1789–1797.
54.
FalagasM.E., MantaK.G., NtzioraF., VardakasK.Z.Line-zolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother.2006; 58(2): 273–280.
NtzioraF., FalagasM.E.Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother.2007; 41(2): 296–308.
57.
RaoN., ZiranB.H., HallR.A., SantaE.R.Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res.2004; (427): 67–71.
58.
RaoN., ZiranB.H., WagenerM.M., SantaE.R., YuV.L.Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis.2004; 38(8): 1058–1064.
59.
SteinmetzM.P., VogelbaumM.A., De GeorgiaM.A., AndrefskyJ.C., IsadaC.Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med.2001; 29(12): 2383–2385.
60.
NtzioraF., FalagasM.E.Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review. Int J Tuberc Lung Dis.2007; 11(6): 606–611.
61.
SoodR., BhadauriyaT., RaoM.Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets.2006; 6(4): 343–354.
62.
CepedaJ.A., WhitehouseT., CooperB.Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother.2004; 53(2): 345–355.
63.
JaksicB., MartinelliG., Perez-OteyzaJ., HartmanC.S., LeonardL.B., TackK.J.Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis.2006; 42(5): 597–607.
64.
MeissnerH.C., TownsendT., WenmanW.Hematologic effects of linezolid in young children. Pediatr Infect Dis J.2003; 22(9 suppl): S186–192.
65.
SaimanL., GoldfarbJ., KaplanS.A.Safety and tolerability of linezolid in children. Pediatr Infect Dis J.2003; 22(9 suppl): S193–200.
66.
YogevR., PattersonL.E., KaplanS.L.Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J.2003; 22(9 suppl): S172–177.
67.
SegalJ.B., MoliternoA.R.Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol.2006; 16(2): 123–130.
68.
FranconiF., BrunelleschiS., SteardoL., CuomoV.Gender differences in drug responses. Pharmacol Res.2007; 55(2): 81–95.
69.
MartinC.M.Gender-specific pharmacology: implications for therapy. Consult Pharm.2006; 21(8): 620–622, 631-624.
70.
AndersonG.D.Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt).2005; 14(1): 19–29.
71.
ChenM.L.Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther.2005; 78(4): 322–329.
72.
GandhiM., AweekaF., GreenblattR.M., BlaschkeT.F.Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol.2004; 44: 499–523.
73.
GochfeldM.Framework for gender differences in human and animal toxicology. Environ Res.2007; 104(1): 4–21.
74.
ShimadaT., YamazakiH., MimuraM., InuiY., GuengerichF.P.Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther.1994; 270(1): 414–423.
75.
FrenchG.Safety and tolerability of linezolid. J Antimicrob Chemother.2003; 51(Suppl 2): ii45–53.
76.
LinY.H., WuV.C., TsaiI.J.High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents.2006; 28(4): 345–351.
77.
Mateu de AntonioJ., GrauS., Morales-MolinaJ.A., Marin-CasinoM., author reply 1501. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Clin Infect Dis.2006; 42(10): 1500.
78.
WuV.C., WangY.T., WangC.Y.High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis.2006; 42(1): 66–72.
79.
SorianoA., OrtegaM., GarciaS.Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother.2007; 51(7): 2559–2563.
80.
MatsumotoK., TakedaY., TakeshitaA.Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents.2009; 33(1): 98–99.
81.
Micromedex Healthcare Series - DRUGDEX System - 2008. Greenwood Village, CO: Thomson Micromedex.
82.
TsujiY., HirakiY., MizoguchiA.Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother.2008; 14(2): 156–160.
83.
AissaouiY., BenkabbouA., AlilouM.[Thrombocy-topenia in a surgical intensive care unit: incidence, risk factors and effect on outcome]. Presse Med.2007; 36(1 Pt 1): 43–49.
84.
BaughmanR.P., LowerE.E., FlessaH.C., TollerudD.J.Thrombocytopenia in the intensive care unit. Chest.1993; 104(4): 1243–1247.
85.
CawleyM.J., WittbrodtE.T., BoyceE.G., SkaarD.J.Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy.1999; 19(1): 108–113.
86.
StraussR., WehlerM., MehlerK., KreutzerD., KoebnickC., HahnE.G.Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med.2002; 30(8): 1765–1771.
87.
BernsteinW.B., TrottaR.F., RectorJ.T., TjadenJ.A., BarileA.J.Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother.2003; 37(4): 517–520.
GrimS.A., ReneL., GuptaS., ClarkN.M.Safety of linezolid in patients with baseline thrombocytopenia. J Antimicrob Chemother.2008; 62(4): 850–851.
90.
WaldrepT.W., SkiestD.J.Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy.2002; 22(1): 109–112.
91.
PlachourasD., GiannitsiotiE., AthanassiaS.No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis.2006; 43(9): e89–91.
92.
SpellbergB., YooT., BayerA.S.Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother.2004; 54(4): 832–835.
93.
YoussefS., HachemR., ChemalyR.F.The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother.2008; 61(2): 421–424.
